Herborium Group, Inc.
E- mail inquiries
Phone: 1 201-849-4431
Herborium Group, Inc.
OTC Pink Current Information OTC Pink Current Information
Shares Outstanding: 715,971,344 a/o August 31, 2012
Float: 520,168,801 a/o August 31, 2012
Authorized Shares: 950,000,000 a/o August 31, 2012 (Par Value 0.001)
HBRM - Daily Candlesticks
We are a unique provider of alternative and complimentary health care solutions in the U.S and global marketplace. We believe that in addition to traditional Western medicine people have the right to benefit from natural medical alternatives rooted in the wisdom of different cultures, which have accumulated over the centuries. It appears that many of you share this opinion since a recent survey conducted by Reuters indicated that nine out of ten Americans believe that alternative therapies may provide effective solutions to health problems. Recently numerous HMOs are adding this option to their treatment offerings.
Our all natural proprietary medicinal products are carefully selected based on their efficacy and safety records and many of them are accepted as mainstream medicines in their country of origin.
Only products that meet our stringent selection criteria are accepted into our product portfolio.
You can think of Herborium as an Alternative Medicine eHelp-Line since our goal is to provide our customers with targeted high quality solutions for their health needs in a personalized manner.
Our pledge to you is not only to deliver the highest quality all natural medicinal products but also to provide you with up-to date, reliable and complete information addressing your concerns and answering your questions. If we do not have an answer for you-we will find it!.
We want to assist you in making your own decisions. The Health Manuals section of our eHelp-Line allows you to make more informed decisions since we supply our customers with detailed information regarding different diseases and health problems that may benefit from our products as well as important data regarding our product portfolio.
For more information visit http://www.herborium.com/
HERBORIUM is working on several additions to its Product Portfolio. The near term products under development and consideration include:
The Liver Activator Series® Complimentary Liver Support Products that target liver damage resulting from Hepatitis C, Hepatitis B, and Cirrhosis and focus on regaining liver wellness compromised by alcohol, drugs and environmental factors. The leading product that supports both liver wellness and treatment is Liver Rejuvenator®
ProstAid an all natural product focused on Benign Prostate Hyperplasia (BPH) and ProstCare a similar product that targets Prostatitis
CardioVitae® a proprietary, fermentation based product using a Lucidium derived cell line targeting cardio-pulmonary insufficiencies. An enriched extract derived from a Ganoderma lucidium cell line that helps improve and accelerate recovery from cerebrovascular strokes is also under consideration.
The Company focuses on health needs with large market potential as defined by the number of patients and the demonstrated need for more satisfactory medical solutions. Additional priority products identified by Herborium include:
- Men's Health (Benign Prostate Hyperplasia)
- Hepatic Disease including Hepatitis and Cirrhosis and Improve hepatic function in patients with chronic liver disease
- Antibiotic resistant pulmonary infections
- Rheumatoid Arthritis
Product Distribution Channels
|Domestic Distribution ||Global Distribution |
- E-Commerce & Affiliates
- Natural Health Products and Natural Food stores& Chains
- Specialty High-end Apothecaries,
- National Upscale Pharmacy chains
- Healthcare Professional Market
- SPAs / Health & Beauty
- Ethnic Markets
- Wholesale Market
- E-Commerce & Affiliates
- Presence in UK & Germany
- Initial Presence in Japan
- Market Entry into India & Brazil
- Healthcare Professional Markets
- SPAs / Health & Beauty
- Targeted Markets ( e.g. male market)
Agnes P. Olszewski, Ph.D. MBA; Founder, President, CEO
Dr. Olszewski, co-founder of Herborium, has over 20 years experience in business strategy, strategic marketing management and international business. She holds an MA and Ph.D. degrees from Warsaw University, Poland, and an MBA from Fordham University, New York City. Dr. Olszewski has been a consultant and a team leader on strategic management and competitive marketing strategies for leading American corporations as well as foreign companies and institutions. In her capacity as an international consultant she had lead multicultural negotiations and managed diverse teams of professionals in the USA, Asia and Europe. She has also been responsible for developing and implementing business and marketing strategies in the US and foreign markets.
Dr. Olszewski's client list includes: AT&T, Johnson & Johnson, Nynex Communications, Unigene Laboratories Inc., Polish Airlines "LOT", Ministry Of Foreign Trade and Economic Collaboration of PRC, UNDP, Graphica Inc. amongst others. She has also been a Small Business Advisor and the Member of the Global Round Table for the State of New Jersey. Dr. Olszewski has been conducting business in China for nearly 20 years.
After the collapse of communism in Central Europe, Dr. Olszewski formed A&T Global Marketing Inc., one of the first consulting firms in the US focusing on the transfer of western management and financial know-how into transitional economies. The company was also involved in advising American corporations on entry strategies into the emerging markets of Europe and Asia. Dr. Olszewski has successfully led the efforts to form Joint Ventures in Poland, China and France. She was a President and CEO of G.O. International, Inc., that she cofounded with Dr. James P. Gilligan, a consulting firm specializing in business strategies for pharmaceutical industry and global technology transfer. G.O. International, Inc. merged with Herborium, Inc. in June 2002.
Prior to starting Herborium, Dr. Olszewski was Director of The Institute for International Business and Director of the MSIB Program at SetonHallUniversity where she is presently a Professor of Marketing and International Business. Dr. Olszewski is the author of over 100 publications and presentations in the US and abroad. She is a Member of The Women's Presidents Organization, an Executive Member of the American Marketing Association, Member of the Academy of International Business, AmericanAcademy of Management, and the International Platform Association. Dr. Olszewski is a recipient of the Valley Forge Foundation National Economic Excellence Award and a recipient of the International Business Award of the State of New Jersey.
James P. Gilligan, Ph.D. MSIB; Co- Founder, Chief Operating Officer
Dr. James Gilligan, a co-founder of Herborium, has over 25 years experience in the pharmaceutical and biotechnology industry, and over 10 years of business experience in China. Dr. Gilligan received his Ph.D. in Pharmacology and Toxicology from the University of Connecticut, during which time he completed a special research fellowship at the Cleveland Clinic Atherosclerosis Research Unit.
He performed his post-doctoral training at the Roche Institute of Molecular Biology. Dr. Gilligan is author or co-author of 15 US patents as well as multiple PCT patents and the author of numerous scientific publications. He also received a MS in International Business from SetonHallUniversity.
Dr. Gilligan is Vice President of Product Development at Unigene Laboratories Inc. Fairfield, NJ, a biopharmaceutical company. He was a founding member of Unigene in 1981 and participated in the design of its R&D facility in 1983 and the cGMP biotechnology manufacturing facility in 1993. His responsibilities have included coordination of all US and international pre-clinical research, toxicology, and regulatory filings as well as design and management of clinical studies. He was an integral part of the team that successfully registered the first "generic" biotechnology product in the EU via a centralized submission. Dr. Gilligan was responsible for coordinating with Warner Lambert (Pfizer) the oral salmon calcitonin program for the treatment and prevention of osteoporosis.
He was also responsible for the US program to register and license Fortical® Nasal Spray, obtain the Company's first NDA approval, as well as identifying new applications for Unigene's technology and negotiations with prospective partners.
Dr. Aihua Qi Vice President, Traditional Chinese Medicine
Dr. Aihua Qi was among the first generation of China' medical experts following the founding of the People's Republic of China, who received eight years of interdisciplinary training in both Western medicine and Traditional Chinese Medicine (TCM). Dr. Qi's professional experience covers the full spectrum of healthcare including: teaching, research and practice in various renowned academic institutions, hospitals and clinics in the capacity of professor, pharmacist, researcher, and physician. She served in leadership positions in a number of projects focusing on: hepatitis, diabetes, anti-frostbite and cardiovascular diseases at leading Government and MilitaryHospitals.
Dr. Qi combined her medical training with an entrepreneurship in the late 1980s when she established and operated private medical clinics in the United States and Hong Kong. Over a period of twenty years in addition to private practice she also developed a number of safe and effective drugs based on unique herbal formulations, representing the innovative combination of western methodology and traditional Chinese medicinal theories. In particular she developed novel herbal medicines that improved liver function in patients with chronic hepatic disease.
Dr. Qi has also developed a formula that targeted dermatological problems related to acne and Rosacea; this product was recognized by the Chinese Ministry of Health as a drug and was granted an NDA. Her outstanding contributions to the field of medicine brought her scientific recognitions as the honorary president of Liaoning Traditional Chinese Medicine Institute, adjunct professor at the 302 Hospital of the Chinese People's Liberation Army, editor to the Chinese Journal of Infectious Diseases, and Council Member to the Liaoning Traditional Chinese Medicine Society, among others.
Dr. Qi is a graduate of AnshanMedicalUniversity where she completed her degree in Western Medicine (1967) and a graduate of Liaoning Traditional Chinese Medical Academic Institute where she specialized in Chinese Medicine.
John E. Donahue, Controller/SEC Advisor
25+ years experience corporate finance, M&A, public accounting
Lawrence Woo, Director; Asia Business Advisor Past President Pfizer Greater China , President Wyeth Pharmaceutical China
Sir Roger Jones (OBE), Director; UK & EU Advisor
Sir Roger Jones, a business entrepreneur, and a former Governor of the BBC and former Chairman of Welsh Development Agency, is Chair to the Panel of the National Assembly for Wales. He is also a past Chairman of the Institute of Directors Wales, and Chairman of the Committee for Wales of the National Trust. Sir Roger is currently the Pro-Chancellor and holds the Chair of Council at Swansea University. He was appointed an OBE in 1996 for his services to the pharmaceutical industry and was knighted in the 2005 New Year honours' list. He is also The Republic of Estonia's first honorary consul in Wales.
Dr. J. Thomas August, MD, Clinical Advisor
Dr. J. Thomas August is a Distinguished Professor at the Department of pharmacology at Johns Hopkins University School of Medicine and is the inventor of the LAMP Technology. Dr. August started his career with a medical degree from Stanford University and trained in medicine as the resident house physician to Sir Stanley Davidson at the University of Edinburgh. His early academic appointments included Assistant Professor of Medicine, Stanford University School of Medicine; Associate Professor of Medicine assigned to Microbiology, New York University School of Medicine and Chairman, Department of Molecular Biology and Director, Division of Biological Sciences, Albert Einstein College of Medicine.
In 1976 Dr. August was appointed Director of Pharmacology and Experimental Therapeutics at Johns Hopkins University School of Medicine. The focus of August research at Johns Hopkins included the use of monoclonal antibodies to identify cellular proteins including discovery in 1980 of a family of lysosome associated membrane proteins (and). Several laboratories with antibodies to LAMP showed its colocalization with the major histocompatibility class II (MHC-II) proteins that acts to deliver the antigenic peptide units of proteins to helper T cells. This finding prompted the development of DNA vaccines encoding antigen proteins as LAMP chimeras areas in order to target and enhance the delivery of the antigens to the helper T cell pathway. This research continues novel epitope-based vaccines to several viral pathogens including HIV, dengue, influenza, West Nile and others. Dr. August honors include appointments as a Markley Scholar in Medical Sciences; Fellow, John Simon Guggenheim Memorial Foundation; Fellow, Balliol College at Oxford University, Adjunct Professor of Medicine, National University of Singapore and an R37 NIAID Merit Award for HIV vaccine research.
Colonial Stock Transfer Co., Inc.
(NOTE: Colonial Stock Transfer's policy is not to give out the share structure of any of the companies they represent.) :(